Skip to main content

Stimufend FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 17, 2024.

FDA Approved: Yes (First approved September 1, 2022)
Brand name: Stimufend
Generic name: pegfilgrastim-fpgk
Dosage form: Injection
Company: Fresenius Kabi USA, LLC
Treatment for: Neutropenia Associated with Chemotherapy, Neutropenia Associated with Radiation

Stimufend (pegfilgrastim-fpgk) is a leukocyte growth factor biosimilar to Neulasta (pegfilgrastim) used to reduce the duration of febrile neutropenia in patients treated with chemotherapy and to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

Development timeline for Stimufend

Sep  6, 2022Approval FDA Approves Stimufend (pegfilgrastim-fpgk), a Biosimilar to Neulasta

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.